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Abstract 
Triple-modal imaging magnetic nanocapsules, encapsulating hydrophobic superparamagnetic iron 
oxide nanoparticles, are formulated and used to magnetically target solid tumours after intrave-
nous administration in tumour-bearing mice. The engineered magnetic polymeric nanocapsules 
m-NCs are ~200 nm in size with negative Zeta potential and shown to be spherical in shape. The 
loading efficiency of superparamagnetic iron oxide nanoparticles in the m-NC was ~100%. Up to 
~3- and ~2.2-fold increase in tumour uptake at 1 and 24 h was achieved, when a static magnetic 
field was applied to the tumour for 1 hour. m-NCs, with multiple imaging probes (e.g. indocyanine 
green, superparamagnetic iron oxide nanoparticles and indium-111), were capable of triple-modal 
imaging (fluorescence/magnetic resonance/nuclear imaging) in vivo. Using triple-modal imaging is to 
overcome the intrinsic limitations of single modality imaging and provides complementary in-
formation on the spatial distribution of the nanocarrier within the tumour. The significant findings 
of this study could open up new research perspectives in using novel magnetically-responsive 
nanomaterials in magnetic-drug targeting combined with multi-modal imaging. 
Key words: PEGylated PLGA, magnetic targeting, optical imaging, nuclear imaging, magnetic resonance im-
aging 
Introduction 
Superparamagnetic iron oxide nanoparticles 
(SPIONs) have been investigated for biomedical ap-
plications.[1, 2] This superparamagnetic property is 
ideal for in vivo use since SPIONs can be highly mag-
netised and literally drag drug molecules to their 
target site in the body under the influence of an ap-
plied magnet field whereas zero remanent magneti-
sation retained after the removal of magnetic field.[2, 
3] SPIONs are frequently used for magnetic drug 
targeting which is regarded as a physical targeting 
method and does not require chemical conjugation of 
targeting ligands.[4] Targeting therapeutic drugs with 
magnetic forces has been proposed to concentrate the 
therapeutic agent at the target site thus lowering the 
administered dosage and reducing systemic side ef-
fects.[5]  
A number of imaging techniques are being ap-
plied for biomedical applications. This includes 
magnetic resonance (MR) imaging, nuclear imaging, 
optical imaging, ultrasound imaging, etc. The 
emerging field of multi-modal imaging using mul-
ti-labelled imaging probes promises to image the 
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same organ with multiple imaging techniques since 
each imaging technique has its own unique ad-
vantages and intrinsic limitation.[6-15] For example, 
MR imaging can offer high spatial resolution (down to 
50-250 µm) and the capacity to simultaneously obtain 
physiological and anatomical information, but sensi-
tivity of MRI is a limiting factor.[16] Optical imaging 
allows for rapid screening and thus is highly desirable 
in clinical and pre-clinical use[17], but is limited by its 
penetration depth in tissues and therefore is consid-
ered to be semi-quantitative. Nuclear imaging offers 
excellent sensitivity (down to 10-10 to 10-12 mol/L) and 
exhibits no limitation for tissue penetration.[16, 18] 
However, image resolution is restricted to the milli-
metre level.[19, 20] Therefore, multi-modal imaging 
systems are required since performing cross-modality 
validation can provide more accurate and reliable 
data than when single imaging modality is 
used.[21-23]  
In this work, we developed a novel approach 
using polymeric nanocapsule to engineer a tri-
ple-modal fluorescence/MR/SPECT imaging system 
and investigated their passive and magnetic targeting 
properties for cancer imaging. To our knowledge, this 
is the first report to examine the magnetic tumour 
targeting of magnetic nanocarrier using tri-
ple-imaging technique. In this study, SPION and a 
near-infrared dye, indocyanine green (ICG), were 
physically incorporated in the magnetic nanocapsules 
as a negative MR contrast agent and fluorescence 
imaging probe, respectively. Furthermore, a chelating 
agent, diethylene triamine pentaacetic acid (DTPA), 
was chemically conjugated to the PEGylated PLGA 
polymer for radio-isotope chelation and therefore 
facilitated nuclear imaging. In vivo studies were per-
formed to characterise the organ biodistribution pro-
file and magnetic targeting of the magnetic nanocap-
sules using triple-modal imaging technique.  
Results and discussion 
Formulation and characterisation of magnetic 
nanocapsules 
Nanocapsules formulations prepared include 
PEGylated poly lactic-co-glycolic acid (PLGA) 
non-magnetic nanocapsules (NC) and magnetic 
nanocapsules (m-NC). PEGylated PLGA18KDa conju-
gate was synthesised and characterised by FT-IR and 
1H-NMR (Additional File 1: Fig. S1). Both formula-
tions were prepared by single emulsification/solvent 
evaporation method (Scheme 1). The hydrodynamic 
size obtained by dynamic light scattering was in range 
of 203 ± 4 nm (Table 1). The inclusion of SPION in 
m-NC did not lead to statistically significant differ-
ence in NC diameter (205 ± 3 nm, p>0.05), however, it 
resulted in a decrease in Zeta potential of NC from -45 
± 2 mV to -36 ± 1 mV (p<0.01) (Table 1). The reduction 
in the overall negative charge of m-NC might be at-
tributed to hydrophobic interactions between the oleic 
acid coatings of SPIONs and the negatively charged 
PLGA polymeric shell. PLGA is FDA approved and 
exhibits high lipophilicity so is ideal to accommodate 
hydrophobic SPIONs coated with oleic acid. SPION 
encapsulation efficiency (EE %) was quantified by 
inductively couple plasma mass spectrometry 
(ICP-MS) after purification by size exclusion chro-
matography. ICP-MS results suggested the SPION 
loading to be 95% ± 3% (equivalent to 1.76%, w/w 
SPION/m-NC, Table 1). This was further confirmed 
by thermogravimetric analysis (TGA) with % weight 
remaining of 1.84% at 600 °C (Additional File 1: Fig. 
S2a).  
Table 1. Physicochemical characterisation of PEGylated NCs 
prepared by single emulsification/solvent evaporation method 
Formulation Initial SPION 
loading (% 
w/w, 
SPION/NC) 
Hydrodynamic 
size ± SD (nm) 
† 
PDI ± SD † Zeta 
potential 
± SD 
(mV) ‡ 
SPION 
EE% ± 
SD $ 
NC - 203 ± 4 0.12 ± 0.01 -45 ± 2 - 
m-NC 1.84 % 205 ± 3 0.16 ± 0.01 -36 ± 1 95 ± 3 
† Size was measured by dynamic light scattering in deionised water (n=3) 
‡ Values were obtained in deionised water (n=3) 
$ Iron content was determined by ICP-MS (n=3) 
 
 
Scheme 1. Preparation of m-NC with triple-modal imaging probes by single emulsification/solvent evaporation method. The m-NC was formulated by the 
emulsification of an organic phase (dichloromethane) containing polymer, oil, lipophilic surfactant, SPION and ICG and an aqueous phase with hydrophilic surfactant using probe 
sonication. Radio-labelling of indium-111 with m-NC was carried out after its formation. 
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The morphology of NCs was examined initially 
by atomic force microscopy (AFM). As shown in Fig. 
1a, NCs and m-NCs were spherical in shape and 
showed a homogeneous size distribution. The phase 
image allows distinguishing different surface features 
and provides significantly more contrast than the 
topographic images, therefore can be useful for com-
positional mapping of surfaces and interfaces of 
polymeric materials.[24] In Fig. 1a, a halo in the pe-
riphery of both types of NCs observed in phase im-
ages suggests that the presence of different materials 
therefore indicating the formation of core-shell struc-
ture. We reported similar observations previously. 
[25] No difference was observed in NC morphology 
with the inclusion of SPION in terms of size and sur-
face features. Low-dose cryo transmission electron 
microscopy (cryo-TEM) was employed to investigate 
the internal structure of m-NCs. Both 2D projections 
and 3D reconstruction suggested that the SPION 
(electron-dense nanoparticle) was homogenously en-
capsulated in the m-NC (Fig. 1b, Additional File 2: 
Movie S1).  
The magnetic properties of SPION and m-NC 
were assessed by measuring the magnetic hysteresis 
curves (Additional File 1: Fig. S2b). The saturation 
magnetisation (Ms) value was ca. 72 emu/g Fe for 
both SPION and m-NC when normalised to the same 
iron content. The coercive field (Hc) was less than 1 
Oe, which is within experimental error of zero, hence 
confirming the superparamagnetic (anhysteretic) 
character of both samples. 
 
 
Figure 1. Morphological examination of m-NC and NC. a, AFM images of NC and m-NC prepared by single emulsification/solvent evaporation method. The height, phase 
images and size histograms of NC and m-NC are presented. Samples were prepared and diluted to 50 µg polymer/ml and freeze-dried on mica slices before imaging. All images 
were acquired while operating in a tapping mode under ambient conditions. A spherical shape was observed in both types of NC with average diameters of 152 ± 25 nm (n=95) 
and 149 ± 30 nm (n=91) obtained for NC and m-NC, respectively. Scale bars are 200 nm. b, Cryo-TEM images of m-NC prepared by single emulsification/solvent evaporation 
method. The CryoTEM projection image, yx and yz orthogonal slices through the 3D tomographic reconstruction of the vitrified sample and a histogram of the size distribution 
of m-NC is presented. CryoTEM measurements demonstrated an average size of 122 ± 4 nm for m-NC. 
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In vivo optical imaging with magnetic targeting 
A near infrared dye, indocyanine green (ICG), 
was incorporated to the NC and m-NC at 0.075% w/w 
ICG/NC. No significant change in hydrodynamic size 
and Zeta potential of NC was observed with the en-
capsulation of ICG (Table 2). To characterise the op-
tical properties of m-NC/NC-ICG, the fluorescence of 
ICG was tested on a well plate at different concentra-
tions in presence of serum. The incubation of m-NC 
with serum showed no influence on ICG fluorescence 
intensity and no quenching effect was seen up to 30 
μg/ ml ICG concentration (Additional File 1: Fig. 
S3a-c). In addition, no significant drop in fluorescence 
intensity was observed when 1.85% SPION (w/w, 
SPION/m-NC) was incorporated compared to 
NC-ICG, however, increasing SPION loading to 7.02% 
w/w caused approximately 41% reduction in fluo-
rescence (Additional File 1: Fig. S3d). Quenching of 
fluorescent imaging probes due to the presence of 
SPION has been reported previously.[26, 27] As a 
result, 1.85% SPION (w/w, SPION/m-NC) was used 
for the in vivo triple-modal imaging studies. 
 
Table 2. Physicochemical characterisation of ICG encapsulated 
NCs prepared by single emulsification/solvent evaporation 
method 
Formulation Hydrodynamic 
size ± SD (nm)† 
PDI ± SD† Zeta potential ± 
SD (mV)‡ 
ICG EE% ± 
SD$ 
NC-ICG 210 ± 8 0.12 ± 0.01 -42 ± 1 98.95 ± 0.63 
m-NC-ICG 207 ± 4 0.16 ± 0.01 -34 ± 1 98.75 ± 0.35 
† Size was measured by dynamic light scattering in deionised water (n=3) 
‡ Values were obtained in deionised water (n=3) 
$ EE% was determined by fluorescence spectroscopy (n=3) 
 
 
m-NC-ICG was intravenously injected into a 
CT26 tumour-bearing balb/c mice and free ICG in 
PBS was injected as a control. Pronounced signals of 
m-NC-ICG were seen over the whole body in Fig. 2a, 
indicating prolonged blood circulation. Tumour ac-
cumulation was observed at 24 h post-injection in live 
animals and ex vivo imaging (Fig. 2b). On the contra-
ry, the mice injected with free ICG showed rapid 
clearance from the body and no sign of tumour ac-
cumulation. The distinct difference in organ biodis-
tribution profiles between the free and encapsulated 
ICG suggested the stable encapsulation of ICG in 
m-NC.  
 
 
Figure 2. In vivo and ex vivo imaging of ICG-labelled m-NC in CT26 tumour-bearing balb/c mice under the influence of magnetic field. Mice were i.v. injected 
with PBS, ICG or m-NC-ICG, respectively. Magnetic field (MF) was applied by placing a permanent magnet (0.515 T) at one tumour (m-TU) for 1 h. a, Representative whole body 
in vivo images of mice obtained at 1, 4 and 24 h post-injection. b, Representative ex vivo images of excised organs at 24 h post-injection. c, Ex vivo quantification of fluorescence 
signals of ICG and ICG-labelled m-NC per gram of tumour at 24 h. d, In vivo quantification of fluorescence signals of ICG per gram of tumour at the magnetically targeted site 
(m-TU) and the non-magnetically targeted site (TU) of mice at different time points. Tumour accumulation in b was observed with mice injected with m-NC-ICG, but not with 
free ICG which exhibited high signals in intestine. Quantitative results also showed significantly enhanced uptake in m-TU compared to TU (*p<0.05, **p<0.01, ***p<0.005). 
Values were expressed as means ± SD (n=3). All images were obtained by IVIS Lumina® III and data were analysed by Living Image® 4.3.1 Service Pack 2 software. 
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Encouraged by the biodistribution and tumour 
accumulation studies of m-NC-ICG, we then investi-
gated the magnetic targeting of m-NC in the same 
tumour model and tumour uptake was monitored in 
vivo by optical imaging. A permanent magnet (0.515 
T) was placed at one tumour site (m-TU) for 1 h. Con-
tra-lateral tumour (TU) was used as an internal con-
trol where no magnet was applied. Interestingly, sig-
nificantly enhanced fluorescence signals at m-TU were 
seen at 1 h immediately after the removal of magnet 
and the increased signals were retained in the tumour 
up to 24 h (Fig. 2a). Ex vivo organ images and quanti-
fication showed that nearly 3-fold increase in fluo-
rescence/g tumour was seen in m-TU compared to TU 
while no significant changes were seen in other or-
gans (Fig. 2c and d). 
Whole body SPECT/CT imaging and gamma 
scintigraphy 
Optical imaging is considered to be a 
semi-quantitative technique due to its limited pene-
tration depth in the body. Thus, to assess the phar-
macokinetic profile and organ biodistribution of 
m-NC quantitatively, SPECT/CT imaging followed 
by ex vivo gamma scintigraphy was performed. The 
m-NC formulation was modified to incorporate 
PLGA18KDa-PEG3.5KDa-DTPA at 10% w/w of total 
polymer content. Both NC and m-NC showed 100% 
radio-labelling efficiency with indium-111 and good 
radio-labelling stability of indium-111 labelled m-NC 
in PBS and 50% serum was also obtained (Fig. 3a and 
b). NC and m-NC without addition of 
PLGA18KDa-PEG3.5KDa-DTPA were included as controls 
and less than 3% labelling efficiency was seen with 
both types of NCs, indicating the radio-labelling of 
indium-111 was due to the chelation with DTPA 
molecule and it was not affected by the presence of 
SPION (Fig. 3a). 
SPECT/CT imaging was performed after i.v. 
administration of 111In labelled m-NC (approximately 
8-10 MBq per injection) in CT26 tumour-bearing mice. 
Three-dimensional reconstruction of the whole ani-
mal by SPECT/CT imaging was conducted immedi-
ately after injection (< 30 min), at 4 h and 24 h 
post-injection (Additional File 1: Fig. S4a). Despite 
the intense radio-activity signals in heart and major 
blood vessels at 0-30 min and 4 h, tumour accumula-
tion started to appear at 4 h post injection (Fig. S4a, 
dashed square) and became clearer at 24 h post injec-
tion due to the enhanced permeability and retention 
(EPR) effect. As expected, predominate tissue accu-
mulation in liver and spleen was also seen due to the 
RES uptake at 24 h. Intense signals were detected in 
kidneys and bladder of mice within 30 min and at 4 h 
post-injection, indicating the renal clearance of con-
stituting polymers. 
Quantitative studies by gamma scintigraphy 
were performed in parallel to SPECT/CT imaging at 
1, 4 and 24 h post-injection of m-NC. In blood clear-
ance profiles (Fig. S4b), 57.0 ± 13.3% ID of m-NC-111In 
was detected in blood at 1 h post-injection and the 
values dropped to 26.8 ± 7.9% and 4.46 ± 0.6 % ID after 
4 and 24 h, respectively. Prolonged blood circulation 
time is considered to be a pre-requisite for EPR effect 
and good tumour uptake.[28] Accumulation of m-NC 
in heart, lung and kidneys decreased over 24 h while 
increasing accumulations were seen in liver and 
spleen with 7.37 ± 0.24% and 12.97% ± 0.5% ID/g at 24 
h, respectively. Negligible radio-activity (~0.15% 
ID/g) was measured in brain at 24h. Tumour uptake 
of m-NC increased from 1.00 ± 0.02% (1 h) to 3.62 ± 
1.42% (24 h) ID/g of tumour (Fig. S4d). The quantita-
tive results provided solid evidence on the long blood 
circulation characteristics and tumour accumulation 
of m-NC over 24 h.  
 
 
Figure 3. Radio-labelling and in vitro serum stability of NC and m-NC. The NC and m-NC were prepared by single emulsification/solvent evaporation method. 
PLGA18KDa-PEG3.5KDa-DTPA was incorporated in the formulation at 10% (w/w). The radio-labelling reaction was carried out for 30 min in 0.2 M ammonium acetate (pH 5.5) and 
quenched by the addition of 0.1M EDTA of 1/20 (v/v) of the total volume. a, Radio-labelling efficiency was evaluated immediately after labelling and 100% radio-labelling efficiency 
was obtained for both types of NCs whereas NCs without incorporation of DTPA showed no radio-labelling. b, Serum stability was tested by incubation of NC-111In and 
m-NC-111In in serum or PBS at 37 °C up to 24 h. Both types of NC exhibited high stability in serum and PBS indicated by presence of low amount of 111In-EDTA. 
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To confirm the magnetic targeting by nuclear 
imaging, the same experiment above was repeated 
except that a magnet was applied on one tumour. 
SPECT/CT imaging and gamma scintigraphy were 
conducted at 1, 4 and 24 h post-injection (Fig. 4). The 
increase in tumour accumulation of m-NC due to the 
magnet application is shown at 1 h post-injection 
(immediately after removal of the magnet) and the 
enhanced uptake could be still seen at 24 h 
post-injection (Fig. 4a). Organ biodistribution profiles 
(Fig. 4b), other than tumour, were similar to that ob-
tained without application magnetic field (Fig. S4d). 
Quantitative gamma scintigraphy studies (Fig. 4c) 
showed that the application of magnetic field in-
creased m-NC uptake in m-TU from 0.87 ± 0.09 % 
ID/g to 2.43 ± 0.27 % ID/g at 1 h post-injection 
(p<0.01) and from 2.92 ± 0.19% to 5.96 ± 0.26% ID/g at 
24 h post-injection (p<0.01). The results suggested 
~3.0- and ~2.2-fold increases in tumour uptake at 1 h 
and 24 h, respectively (Fig. 4d).  
 
 
Figure 4. In vivo SPECT/CT imaging and organ biodistribution studies of m-NC-111In in CT26 tumour-bearing balb/c mice under the influence of magnetic 
field. Mice were i.v injected with m-NC-111In (8-10 MBq per mouse). A permanent magnet (0.515 T) was applied at one tumour site (m-TU) for 1 h. Organs were excised at 1, 
4 and 24 h post-injection for gamma counting. a, Whole body 3D SPECT/CT imaging at 1, 4 and 24 h post-injection. Cross-sections were from lung (LU), liver (LI), spleen (SP), 
kidney (KI), non-magnetically targeted tumour (TU) and magnetically targeted tumour (m-TU) at equivalent time points; Tumours are marked in dashed square; b, Organ 
biodistribution profile with values expressed as % ID/g of organ. c, Quantification of % ID/g of tumour in m-TU and TU at different time points; d, Fold increase in % ID/g of tumour 
(%ID/g m-TU/%ID/g TU) upon application of magnetic field. Significant increase in tumour uptake was shown upon application of a magnet at all time points (**p < 0.01). Results 
are expressed as mean ± S.D. (n=3). 
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Animals were also housed in metabolic cages for 
urine and faeces collection up to 24 h to assess excre-
tion profile. Relatively high amount of radioactivity 
(37.57 ±15.41 % ID/mouse) was eliminated into urine 
within 24 h (Fig. S4c). No 111In-DTPA/EDTA chelates 
were detected in the urine samples by TLC, therefore 
indicating the presence of 111In-labelled polymers in 
urine due to disassembly of m-NC-111In (data not 
shown). Unlike the high radio-activity detected in 
urine sample, negligible values (< 1% ID/mouse) 
were detected in faeces within 24 h, suggesting lim-
ited biliary excretion.  
Some studies questioned if the apparent target-
ing effect is due to an increased amount of magnetised 
nanoparticles within the tumour vasculature under 
the influence of magnetic force.[29, 30] Since im-
age-based results cannot fully discriminate the pres-
ence of m-NC in tumour vasculature or tumour mass, 
the distribution of m-NC in tumour tissues was fur-
ther investigated after whole body saline perfusion 
prior sacrificing the animals (Additional file 1: Fig. 
S5). Perfusion resulted in non-significant reductions 
(p>0.05) in non-magnetic tumour uptake from 0.87 ± 
0.09 % and 2.92 ± 0.19% to 0.79 ± 0.03% and 2.55 ± 
0.19% ID/g after 1 and 24 h, respectively (Fig. S5b). 
Interestingly, no reduction in tumour accumulation at 
the magnetically-targeted tumour site occurred after 
perfusion at all time points, which confirmed that 
m-NC was localized in the tumour mass and not stuck 
in tumour vasculature. In addition, the different tu-
mour uptake profiles of m-TU and TU obtained with 
or without perfusion also suggested that the applica-
tion of magnetic field not only helped the accumula-
tion of m-NC at tumour site but the m-NC was capable 
of extravasation into tumour mass.  
In vivo MR imaging 
Owing to the intrinsic MR contrast properties of 
SPION, the m-NC distribution in tumour was further 
monitored by in vivo MR imaging, an imaging tech-
nique providing high resolution images and excellent 
soft tissue contrast. The tracking of the biodistribution 
of encapsulated SPIONs upon application of magnetic 
field was also indirect evidence on the stability of 
SPION in m-NC in vivo. The MR contrast properties of 
SPION and m-NC were evaluated in vitro using 1% 
agarose phantom (T2 = 15 ms, Fig. 5a). The transverse 
(T2) relaxation times were measured at different con-
centrations and R2 values were calculated. Interest-
ingly, m-NC exhibited higher r2 relaxivity (404 mMs-1) 
compared to the non-encapsulated SPION (260 
mMs-1) (Fig. 5b) and the commercial Feridex I.V.® 
(224 mMs-1 reported in the literature) [11]. The high r2 
relaxivity is likely due to the clustering of SPION in 
m-NC, which was shown in the cryo-EM images, 
thereby enhancing the local magnetic field.[31-33] A 
higher molar relaxivity is important especially for 
applications such as tumour MR imaging due to the 
low sensitivity of MRI and low tumour accumulation 
of contrast agents compared to RES organs i.e. liver 
and spleen, when conventional MRI contrast agents 
are used. 
In vivo MR imaging was performed at m-NC 
pre-injection and at 1, 4, 24 h post injection of m-NC. 
The representative coronal T2-weighted images at an 
acquired echo time of 15 ms are shown (Fig. 5c) and 
the R2 relaxation rates of tumours and adjacent mus-
cles at different post-injection time are shown in Ad-
ditional file 1: Fig. S6. As expected, the R2 relaxation 
rates of the tumour-adjacent muscle tissues reported 
similar values to that of pre-injected muscles at any 
post-injection time point (Fig. S6a). In contrast, 
pre-injected tumours appeared brighter than muscles 
and both m-TU and TU were darkened after injection 
(Fig. 5c, dashed lines). Such lack of MRI signals cor-
responded to a shortening in R2 values (Fig. S6b). The 
tumour accumulation and magnetic targeting effect of 
m-NC was expressed as time-course percentage 
changes in transverse relaxation rate (dΔR2) over the 
whole tumour area (Fig. 5c, dashed lines). After ad-
ministration of m-NC, a significant increase in dΔR2 
(40.24 ± 4.61%) was seen in the non-magnetically tar-
geted tumours at 1 h post-injection and the percentage 
increased to 57.0 ± 03.87 and 64.04 ± 4.34% at 4 and 24 
h, respectively, as a result of passive accumulation of 
m-NC (Fig. 5d). Compared to the non-magnetically 
targeted site, more significant darkness was observed 
in m-TU upon application of magnetic field, with 
dΔR2 increased to 80.07 ± 7.23% (p<0.05), 91.55 ± 
6.65% (p<0.05) and 97.71 ± 5.55% (p<0.01) at 1,4 and 
24 h (Fig. 5d), respectively, representing a 2.09-, 1.57- 
and 1.51-fold increase compared to the non-targeted 
tumour (Fig. 5e), respectively. The decreasing ten-
dency in dΔR2 fold increase could be attributed to the 
EPR effect over time and these results were in line 
with the data obtained from gamma scintigraphy 
studies. In our studies, the T2 hypointensity (darken-
ing) caused by the high SPION accumulation was 
observed at m-TU as early as 1 h post-injection, sug-
gesting that the proposed m-NC offered sufficient 
sensitivity to be monitored in tumours, and also con-
firmed the success of magnetic targeting in vivo.  
In most previous magnetic targeting studies, the 
magnetic targeting effect was investigated by MR 
imaging only as SPION is MR active and drugs were 
either chemically conjugated or physically absorbed 
in the coating matrix of magnetic nanoparticles 
(MNP)/ferrofluid. [34-41] In this work, a mul-
ti-functional m-NC was developed to facilitate mag-
netic targeting to tumour. Nanocapsules contain an 
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oily core to solubilise and encapsulate a relatively 
large quantity of hydrophobic molecules, thus can 
serve as drug reservoirs with sustained release of an-
ti-cancer agents.[25] The m-NC was also capable of 
incorporating with three different imaging moieties, 
i.e. NIR dye, SPION and radio-isotope chelator, as a 
multi-modal imaging probe. The time-course organ 
distribution and tumour retention of the magnetic 
nanocarrier as a function of magnetic field could 
therefore be monitored with triple-modal fluores-
cence/MR/SPECT imaging modalities. Optical im-
aging is known to be limited by the depth of light 
penetration due to its scattering and tissue absorption 
[42]. It is therefore considered to be a 
semi-quantitative imaging tool. However, the short 
acquisition time and low-cost of optical labelling 
methods make it a fast-screening and lead selection 
tool in cancer theranostics. Contrary to optical imag-
ing, nuclear imaging permits accurate and sensitive 
quantification of m-NC biodistribution. Organ distri-
bution, blood circulation, excretion profiles, tumour 
accumulation and magnetic targeting efficacy of 
m-NC were obtained from SPECT/CT imaging and 
gamma scintigraphy.  
 
 
 
Figure 5. Phantom and in vivo T2-weighted MR studies of m-NC in CT26 tumour-bearing balb/c mice under the influence of magnetic field. Phantom samples 
of SPION and m-NC were prepared in 1% agarose. Images were obtained using a 7 Tesla (7 T) preclinical MR scanner. a, Phantom MR imaging of m-NC and SPION. b, R2 
relaxation rate analysis as a function of Fe concentration. For in vivo MR study, mice were i.v injected with m-NC at a dose of 125 mg SPION/Kg. A permanent magnet (0.515 T) 
was applied at one tumour site (m-TU) for 1 h. c, MR images of tumours at 0, 1, 4 and 24 h post-injection. Tumours are marked in dashed lines. d, Percentage changes in transverse 
relaxation rates (dΔR2) in magnetically targeted tumour (m-TU) and non-magnetically targeted tumour (TU) over time. e, Fold increase in dΔR2 in m-TU compared to TU as a 
function of time; Significant increase in tumour uptake was shown upon application of a magnet at all time points (*p<0.05, **p<0.01). Results are expressed as mean ± SD (n= 
3). 
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In addition to the whole body biodistribution, 
the high spatial resolution MR images provided the 
regional distribution profiles of m-NC in tumours. 
The fold increase in m-TU accumulation obtained by 
MRI was slightly lower than the values offered by 
nuclear imaging. This is likely due to lower sensitivity 
of MRI compared to SPECT. Weak interactions be-
tween MRI static magnetic field and body tissues re-
sult in high signal-to-noise ratio and limit MRI sensi-
tivity to 10−3 -10−5 mol/L, whereas nuclear imaging 
has a significantly higher sensitivity of 10-10- 10-12 
mol/L.[43] As a result, the latter is more accurate and 
reliable for quantification. In this work, similar trend 
of magnetic targeting efficacy over time was observed 
in tumours with both techniques. The highest fold 
increase in m-TU uptake was seen at 1 h 
post-injection, immediately after the magnet removal. 
The reduction at 4 and 24 h was a result of the EPR 
effect taking place in both TU and m-TU over time. 
The good correlation between information obtained 
from MRI (SPION) and SPECT (polymeric shell), 
however, suggests that most of the SPION was stably 
encapsulated and remained in the m-NC when mag-
netically targeted to tumours. On the other hand, MRI 
provides high spatial resolution up to 50–250 μm 
while SPECT imaging is limited to only 0.3–1 mm[43] 
The hypointense signals in MR images from m-NC 
were shown in tumours in a heterogeneous manner 
and this could be due to the regional differences in 
tumour growth rates, vascular densities, vascular 
permeability and presence of other tumour-associated 
cell types.[17] The heterogeneous distribution of 
m-NC in tumours was likely to be a result of an in-
homogeneous tumour blood vessel pattern, therefore 
the hypointense regions might correlate to areas of 
high vascularity.[33]  
At the current stage, magnetic targeting is con-
sidered for loco-regional treatment of cancers that are 
close to body surface, i.e, advanced head and neck 
tumours, skin tumours and breast cancer.[44, 45] At-
tenuated gradients pose a translational challenge for 
target sites located in deep tissues, as magnetic flux 
density wears off dramatically with distance.[46, 47] 
To overcome these barriers, a number of studies have 
been proposed to generate localised magnetic field 
using implanted magnets near the targets. [48, 49] 
Alternatively, magnetic flux density can be focused 
from a distance through the use of custom designed 
magnetic devices. The latter approach is currently 
under investigations, for magnetic cell delivery, and is 
claimed to be suitable for deep tissue magnetic cap-
ture.[50] 
Histological examination  
Cytotoxicity of four types of NCs, namely 
non-PEGylated NC/m-NC and PEGylated 
NC/m-NCs was assessed in CT26 cells in vitro by MTT 
assay. As expected, all types of NC formulations 
showed no significant reduction in cell viability, 
compared to naive group, over 72 hours at maximum 
polymer concentration that might accumulate in tu-
mour in vivo (Additional file 1: Fig. S7). Histological 
examination of fixed and stained tissue sections was 
performed at 24 h post-injection. H&E staining 
showed no major signs of necrosis in heart lung, liver, 
spleen and kidneys of mice injected with NC and 
m-NC at 24 h post-injection (Fig. 6). No extended tu-
mour necrosis was seen in all treated tumours with or 
without magnetic field in NC and m-NC injected mice 
compared to control. Mice injected with m-NC 
showed brownish spots seen evenly distributed in 
liver, spleen and some areas of the magnetically tar-
geted tumour, indicating the presence of SPION (Fig. 
6, red arrows). 
Perl’s staining was employed to confirm the 
presence of iron in tissues (Fig. 6, black arrows). No 
positive signs of iron were seen in control organs ex-
cept for spleen where blue spots were seen due to 
endogenous iron.[51] Very few blue-stained regions 
were observed in lung of m-NC treated mice whereas 
strongly positive signals were homogenously distrib-
uted in liver and spleen, which co-localized with the 
brownish spots observed in H&E stained sections 
(Fig. 6, red arrows). More importantly, a number of 
positive blue signals appeared in m-TU of mice ad-
ministrated with m-NC while only a few spots were 
seen in TU, indicating the significant increase in m-NC 
tumour uptake as a result of magnetic targeting. 
Conclusions 
A polymeric nanocapsule formulation for tri-
ple-modal fluorescence/MR/SPECT imaging and 
magnetic targeting was developed. m-NC was capable 
of encapsulating a high amount of SPION, which was 
crucial to achieve magnetic drug targeting and MRI in 
vivo. NIR dye (ICG) and radio-isotope chelator 
(DTPA) were either physically encapsulated or 
chemically conjugated to the m-NC to facilitate optical 
imaging and nuclear imaging, respectively. Optical 
imaging was proven to be a fast-screening method to 
assess the tumour uptake and the long circulation 
property of m-NC whereas SPECT/CT imaging al-
lowed quantitative assessment of organ biodistribu-
tion, passive tumour accumulation and magnetic tar-
geting efficacy of m-NC. High resolution MR imaging 
showed heterogeneous distribution patterns of m-NC 
in tumours, indicating that the proposed m-NC of-
fered sufficient sensitivity to monitor its tumour up-
take and magnetic targeting in vivo. Time-course op-
tical/MR/SPECT imaging studies showed enhanced 
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tumour uptake upon the application of the external 
static magnetic field at tumour site. Magnetic target-
ing led to ~3 and ~2.2 fold increase in tumour uptake 
at 1 and 24 h, respectively compared to only passive 
targeting. Findings from this work demonstrated the 
capability of the m-NC to be used as a triple-modal 
imaging nanocarrier for cancer magnetic targeting in 
vivo.  
 
Figure 6. Microscopic examination of lung, liver, spleen and tumour sections of CT26 tumour-bearing balb/c mice. Mice were intravenously injected with NC 
(left panel) and m-NC (right panel) with application of magnet at one tumour site (m-TU). Organs were sampled at 24 h post-injection, sectioned and stained with H&E and Perl’s 
staining. Red and black arrows point to the presence of iron in H&E (brownish spots) and Perl’s staining (blue stains), respectively. H, K and W, R stands for hepatocytes, Kupffer 
cells in liver and white pulp, red pulp in spleen, respectively. Scale bars are 30 µm. No histological abnormalities were observed in all organs at 24 h post-injection. Increased 
amount of blue spots could be seen in the magnetically targeted tumour, indicating the enhancement in m-NC tumour uptake by magnetic targeting. 
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Materials and methods 
Materials 
SPION (oleic acid coated iron oxide nanoaprti-
cles with diameter of 10 nm, 1017 particles per ml) was 
purchased from Magnacol Ltd (UK). Soybean lecithin 
(Epikuron 140 V) was a kind gift from Cargill Phar-
maceuticals (USA). Polyoxyethylene-bis-amine 
(NH2-PEG3.5KDa-NH2) was purchased from JENKEM 
(USA). D/L-lactide/glycolide copolymer 75/25 
(PLGA18KDa-COOH) was purchased from Purac Bio-
materials (Netherlands). Tween® 80 was obtained 
from Fisher Scientific Ltd (UK). Sodium chloride, 
phosphate buffered saline tablets, dicyclohexylcar-
bodiimide (DCC), N-Hydroxysuccinimide (NHS), 
anhydrous dimethylformamide (DMF), diethylene 
triamine pentaacetic acid (DTPA), castor oil and po-
tassium permanganate were purchased from Sigma 
Aldrich (UK). Indocyanine green (ICG) was pur-
chased from MP Biomedicals (USA). Dichloro-
methane (DCM), isopropanol, dimethylsulphoxide 
(DMSO), triethylamine (Et3N) and diethyl ether were 
obtained from Fisher Scientific Ltd (UK). Advanced 
RPMI-1640 media, penicillin-Streptomycin 100x, 
Trypsin-EDTA (1X) with Phenol red Glutamax™ 
supplement, phosphate buffered saline PBS (10x, pH 
7.4) were obtained from Gibco, Invitrogen (UK). 
Plasma derived Bovine serum (FBS) was obtained 
from First-Link Ltd (UK). Pentobarbital sodium (Eu-
thatal®) was obtained from Merial (UK). SP-Sephadex 
C25 cation-exchanger column was obtained from 
Phenomenex Inc (USA). C18 Sep-Pak® Vac column 
was purchased from Waters Ltd (USA). Dialysis tub-
ing SnakeSkin (MWCO 10 KDa), black 96 well-plates 
and autoclave tapes were purchased from Ther-
mo-fisher Ltd. (USA). Dialysis tubing (MWCO 2 KDa) 
was obtained from Sigma Aldrich (UK). Disposable 
square polystyrene cuvettes and disposable capillary 
cells were purchased from Malvern Instrument (UK). 
Mica sheets (11 mm x 11 mm x 0.15 mm) were used 
for atomic force microscopy experiments (AFM). 
PD-10 desalting column was obtained from GE 
Healthcare Life Sciences (UK). All the reagents were 
analytical grade and used without further purifica-
tion. 
Formulation of the m-NCs 
PLGA18KDa-PEG3.5KDa-NH2 and 
PLGA18KDa-PEG3.5KDa-DTPA were synthesised as de-
scribed in supplementary method. The PEGylated 
m-NC was prepared by single emulsification/solvent 
evaporation method. Briefly, polymer (12.5 mg), cas-
tor oil (75 mg), soybean lecithin (25 mg) and SPIONs 
(2.5 mg) were dissolved in 2.5 ml dichloromethane. 
The organic phase was poured into an aqueous phase 
(5 ml) containing Tween® 80 (20 mg). The resultant 
dispersion was emulsified by ultra-sonication, fol-
lowed by organic phase evaporation. The obtained 
m-NC suspension was further condensed by 10 or 20 
times with final polymer concentration of 25 (for op-
tical or MR imaging) or 50 mg/ml (for SPECT/CT). 
Size and Zeta measurements 
The hydrodynamic size (Z-Average), polydis-
persity index (PDI) and Zeta potential of the NC were 
determined by NanoZS (Malvern Instrument, UK) 
using disposable square polystyrene cuvettes (Mal-
vern Instrument, UK) for size and PDI, or disposable 
capillary cells (Malvern Instrument, UK) for Zeta po-
tential at 25°C. For size measurement, NC samples 
were diluted with deionised water. The Z-Average 
diameter and polydispersity index were presented as 
the average value of three measurements, with 15 
runs within each measurement. Electrophoretic mo-
bility was used to calculate the Zeta potential meas-
urement. NC samples were diluted with deionised 
water. Three measurements were performed with 
20-25 runs within each measurement. The mean and 
standard deviation of size and Zeta potential were 
calculated for each sample. 
Atomic force microscopy (AFM) of m-NC 
The surfaces for AFM analysis were prepared as 
follows: The different NC formulations were filtrated 
through a PD-10 desalting column and solutions of 50 
μg/ml were prepared. NC suspensions (500 µl) were 
deposited on a new piece of mica and lyophilised us-
ing a Lytrap freeze-dryer (LTE Scientific, UK). Tap-
ping mode AFM analysis (TM-AFM) on the mica 
substrates was carried out in air at 25 ⁰C using a 
Bruker Dimension ICON with Scan Assist. The sur-
faces were imaged with a general purpose tapping tip 
made by MikroMasch in Estonia (NSC15/no Al, tip 
radius <10 nm; tip height = 20 - 25 μm; cone angle <40; 
cantilever thickness = 3.5- 4.5 μm; cantilever width = 
32 - 28 μm; cantilever length = 120 - 130 μm; frequency 
f0 = 265 - 400 kHz; force constant k = 20 - 75 N m-1, 
VEECO, USA). The statistical analysis of the AFM 
images was carried out using WSxM v5.0 software 
(Spain). 
Cryo Transmission Electron Microscopy 
(Cryo-TEM) of m-NC 
The shape, morphology and size distribution of 
the nanocapsules was evaluated using low-dose 
cryo-transmission electron microscopy (cryo-TEM) 
and cryo electron tomography. Cryo-TEM enables the 
investigation of colloidal solutions close to their na-
tive state. A drop of solution (3µL) was applied on 
hydrophilic TEM Quantifoil grids. The grids were 
then blotted for 2 sec and plunged into the liquid 
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ethane pool using a FEI Vitrobot mark IV, in order to 
produce a thin vitreous ice layer with embedded as-
semblies in the holes of the grid. Digital cryo-TEM 
images were acquired using a FEI Tecnai Spirit oper-
ated at 120kV using a Gatan 626 cryo-transfer to-
mography holder. The tomographic series was ac-
quired using automated acquisition software 
Xplore3D from FEI. Next, the series was aligned and 
reconstructed using the simultaneous iterative recon-
struction technique (SIRT) based on 30 iterations car-
ried out using the FEI inspect 3D tomography pack-
age. The measurements of size distribution were car-
ried out in Amira (3D visualisation software). 
Thermogravimetric Analysis (TGA) of SPION 
and m-NC 
The amount of oleic acid coating on the SPION 
and the weight percentage of SPION in m-NC were 
characterised by the thermogravimetric analysis 
(TGA) using TGA Q500 (TA instrument), where about 
10 mg of SPION was loaded into platinum pan. The 
measurement was pre-equilibrated at 100 °C and then 
heated from 100 °C to 1000°C with a temperature 
ramp of 10 °C/min under compressed air atmosphere 
with balance and sample purge flow at 10 and 90 
ml/min, respectively.  
Encapsulation efficiency of SPION in m-NC 
The SPION encapsulation efficiency was deter-
mined by inductively couple plasma mass spectrom-
etry (ICP-MS). m-NCs with 1.85% w/w SPION/m-NC 
(corresponding to 20% w/w SPION/polymer) were 
prepared and purified by size exclusion chromatog-
raphy (G75 column) to remove any un-encapsulated 
SPION. For ICP-MS measurements, suitable dilutions 
of Fe standards (Leeman Labs Inc., MA) were pre-
pared in 20% nitric acid to obtain a standard curve in 
the range of 10-10000 parts per billion with respect to 
Fe. m-NC samples were digested in 2 ml of nitric acid 
and incubated overnight at 50 °C. The resulting solu-
tion was diluted to reach concentration calibration 
range. The Fe content was determined by inductively 
couple plasma mass spectrometry (Perkin Elmer 
SCIEX ICP mass spectrometer, ELAN DRC 6100, 
USA).  
Radio-labelling of NCs and serum stability 
studies 
The radioactive probe 111InCl3 was purchased 
from Mallinckrodt Pharmaceuticals (The Nether-
lands) as an aqueous solution in 0.5 M HCl and used 
without further purification. To radio-label the NC 
and m-NC with indium-111, NCs were prepared as 
described in the previous section except that 
PLGA18KDa-PEG3.5KDa-DTPA was included at 10% 
(w/w) of total polymer content. The NC suspension 
(150 µl, 50 mg/ml of polymer) was incubated with 2 
M ammonium acetate (one ninth of the reaction 
volume, pH 5.5), to which 10 MBq or 1 MBq as 111InCl3 
was added per injection dose for SPECT/CT imaging 
and gamma scintigraphy, respectively. The reaction 
was kept at room temperature for 30 min with inter-
mittent vortexing every 10 min. Upon completion, the 
radio-labelling reaction was quenched by the addition 
of 0.1 M EDTA chelating solution (one twentieth of 
the reaction volume). 111InCl3 alone was also subjected 
to the same conditions of the labelling reaction as a 
control. 
To evaluate the radio-labelling efficiency, the 
labelled NC-111In and m-NC-111In were spotted on the 
TLC strips which were developed in 0.1 M ammo-
nium acetate containing 50 mM EDTA as a mobile 
phase. Strips were allowed to dry before being de-
veloped and counted quantitatively using a cyclone 
phosphor detector (Packard Biosciences, UK). The 
NC-111In and m-NC-111In were passed through PD-10 
column before injecting into animals to exchange the 
ammonium acetate buffer (pH 5.5) with PBS (pH 7.4) 
and to ensure that no free 111In-EDTA was present in 
the injected dose. The NC-111In and m-NC-111In (~150 
µL per injection dose, 25 mg/ml of polymer) were 
collected from the column and the radio-labelling 
efficiency was examined immediately after collection 
from the column.  
To determine the stability of the radio-labelled 
NC-111In and m-NC-111In, 5 µL of each sample was 
incubated with serum (5 µL) and PBS (5 µL) at 37 °C. 
At 24 h, 1 µL of the incubated samples were spotted to 
the TLC strips and which were developed, and quan-
tified as described above. Free 111In-EDTA was de-
tected at the solvent front while radio-labelled NCs 
were retained at the application point.  
Animal studies and tumour inoculation 
All animal experiments were performed in 
compliance with the UK Home Office (1989) Code of 
Practice for the housing and care of Animals used in 
Scientific Procedures. The CT26 murine colon carci-
noma (CT26, ATCC®, CRL-2638TM) were cultured in 
Advanced RPMI (Roswell Park Memorial Institute) 
1640 medium supplemented with 1% L-glutamine, 1% 
penicillin-streptomycin and 10% fetal bovine serum 
(FBS) with 5% CO2 and 95% air at 37 °C. The har-
vested CT26 cells were suspended in PBS solution 
(pH 7.4) and injected subcutaneously and bifocally in 
the hind foot of the female Balb/c mice aged 4-6 
weeks (Harlan, UK) at a concentration of 1×106 cells in 
20 µl. After inoculation, the tumour volume was 
measured on day 7 and then every other day using a 
digital caliper and calculated using Equation (1): 
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Tumour volume (mm3) = (4/3) * π (A/2)2 *(B/2) 
=0.52A2B       …(1) 
where A and B represent the width and the length of 
the tumours, respectively.[52] 
All experiment was carried out when the tumour 
volume reached approximately 500 mm3 at approxi-
mately about 11-12 days post-injection. 
In vivo optical imaging studies 
Optical imaging was performed using an IVIS® 
Lumina series III In Vivo Imaging Device (Caliper Life 
Sciences, Perkin Elmer, USA). CT26 tumour-bearing 
mice were injected intravenously at a dose of 312.5 mg 
PLGA18KDa-PEG3.5KDa-NH2/Kg, 125 mg SPION/Kg (70 
mg Fe/Kg) and 250 μg ICG/Kg. Images of mice were 
captured for the same animals at 1, 4 and 24h 
post-injection. At 24h post-injection, major organs, i.e. 
heart, lung, liver, spleen, kidneys, intestine and tu-
mours were excised and imaged on a black surface 
(Caliper Life Sciences, Perkin Elmer, USA). Fluores-
cence images was obtained using ICG filter (680, 700, 
720, 740, 760, 780/845 nm for excitation/emission 
wavelengths) with exposure time of 8 s. The collected 
fluorescence emission signals were stored in efficien-
cy units. 
Live small animal SPECT/CT imaging studies 
m-NC was radio-labelled with indium-111 as 
described in previous sections. Whole body imaging 
of mice injected with m-NC-111In was carried out us-
ing SPECT/CT imaging. CT26 tumour-bearing Balb/c 
mice were injected intravenously via a lateral tail vein 
with 150 μl PBS solution containing 8-10 MBq 
m-NC-111In (corresponding to 312.5 mg polymer/Kg 
and 125 mg SPION/Kg or 70 mg Fe/Kg). The imaging 
was carried out at 0-30 min, 4 h and 24 h post-injection 
under anaesthesia of 1.5% isoflurane/98.5% oxygen 
using Nano-SPECT/CT scanner (Bioscan, Washing-
ton DC, USA). SPECT acquisitions were obtained us-
ing 16 projections over 40-60 min using a four-head 
scanner with 1.4 mm pinhole collimators. CT scans 
were carried out after the SPECT acquisition. SPECT 
and CT images were analyzed using InVivoScopeTM 
software (Bioscan, Washington DC, USA). 
Quantitative biodistribution studies by gamma 
scintigraphy 
Organ biodistribution studies of m-NC-111In in-
cluding organ biodistribution, blood circulation and 
excretion profile were performed in CT26 tu-
mour-bearing balb/c mice using gamma scintigraphy 
to obtain quantitative data. Mice were randomly di-
vided into four groups of three mice each and as-
signed as 1h, 4h, 24h and control group. Mice were 
injected intravenously via a lateral tail vein with 150 μl 
PBS solution containing ~0.7 MBq m-NC-111In (corre-
sponding to 312.5 mg polymer/Kg and 125 mg 
SPION/Kg or 70 mg Fe/Kg). Blood sample (5 μl) was 
collected from the tail vein at 2 min, 5 min, 10 min, 30 
min, 1 h, 4 h and 24 h post-injection. Tumours and 
other tissues, i.e. skin, liver spleen, heart, lung, mus-
cle, bone, brain, stomach, intestine, tail and carcass 
were removed, weighed, and the radioactivity was 
measured by a gamma counter (1280 CompuGamma 
Universal Gamma Counter, LKB Wallac, Finland), 
using the appropriate energy windows for 111In. Re-
sults were expressed as percentage of injected dose 
per organ (% ID/organ) and percentage of injected 
dose per gram organ (% ID/g) as means ± SD (n=3).  
In vitro and in vivo MR Imaging 
Phantom and in vivo MR imaging were per-
formed at a 7T horizontal MR scanner (Agilent, Palo 
Alto, CA). The gradient coil had an inner diameter of 
12 cm, gradient strength was 1000 mT/m (100 G/cm) 
and rise-time of 120 µs. A quadrature trans-
mit/receive coil (RAPID Biomedical GmbH, Germa-
ny) with an internal diameter of 39 mm was used. 
Animals were intravenously injected with m-NC at 
the same dose used for optical imaging and imaged at 
0, 1, 4 and 24 h post injection. A spin-echo MRI tech-
nique where echo times (TE) were varied, was used to 
acquire T2-weigheted images both in vitro and in vivo. 
The spin-echo parameters in phantoms were: FOV = 
30 × 30 mm, matrix size = 96 × 96, slice thickness = 1 
mm; number of slice = 1; 1 average, TR = 2000 ms; TE 
= 10, 30, 50, 75, 100 and 125 ms; scan time ~20 min. For 
in vivo acquisitions FOV was changed to 25 × 25 mm 
and matrix size to 128 × 128. A short-axis and a long 
axis view were used for the in vivo experiment. MR 
images were analysed using the ImageJ software 
(NIH, USA). For in vivo studies, R2 values of m-TU and 
TU were obtained from the mean signal intensity in 
defined regions of interest shown as dashed line 
(whole tumour area) in MR images. The R2 values of 
adjacent muscle were used as a reference to the mag-
netic targeting enhancement R2 values. The changes in 
R2 due to the presence of m-NC in tumour were ex-
pressed as percentage changes of the initial 
(pre-injection) relaxation rate by Equation (2) for all 
animals at all time points:  
dΔR2= (R2 post - R2 pre)/ R2 pre ×100%       …(2) 
Magnetic targeting studies in tumour-bearing 
mice 
Magnetic targeting studies were carried out in 
the same tumour model at the same dose of m-NC 
described in previous sections. An 8 mm diameter 
disk neodymium magnet (first4magnet, UK), rated 
0.515 Tesla at its face surface, was placed 
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non-invasively over the surface of one of the tumours 
and retained using autoclave tapes. The other site of 
tumour was used as an internal negative control as no 
magnet was applied. After 1 h, the magnet was re-
moved from the mice. The procedures of optical, MR 
and SPECT/CT imaging were carried out as de-
scribed in previous sections.  
Hematoxylin and Eosin (H&E) stain of tissue 
sections 
Small pieces (~5 mm2) of major organs i.e. heart, 
lung, kidney, liver, spleen and tumour tissues, from 
animals exposed to NCs and magnet, were immedi-
ately fixed in 10% neutral buffered formalin. Samples 
were then wax-embedded and sectioned for haema-
toxylin and eosin stains (H&E) according to standard 
histological protocols at the Royal Veterinary College, 
UK.  
Perl’s staining of tissue sections 
To detect the presence of iron in tissues, Perl’s 
staining was carried out using a Perl’s stain kit used 
according to the manufacturer's instruction. In brief, 
sections were de-paraffinised and incubated with 
potassium ferrocyanide solution for 20 min followed 
by counterstaining with nuclear red solution for 10 
min. Sections were then dehydrated using increasing 
concentrations of ethanol solutions (50%, 70%, 90%, 
and absolute ethanol), cleared by xylene and mounted 
in DPX (Distrene, Plasticiser, Xylene) mounting me-
dia. All stained sections were analysed using a Leica 
DM 1000 LED Microscope (Leica Microsystems, UK) 
coupled with CDD digital camera (Qimaging, UK). 
Statistical Analysis 
Quantitative data are presented as mean ± 
standard deviation (SD). Paired sample T tests were 
performed using IBM SPSS version 20. The t-value, 
degrees of freedom and two-tailed significance 
(p-value) were determined. When p-values were 0.05 
or less, differences were considered statistically sig-
nificant. 
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